Chris Shibutani
Stock Analyst at Goldman Sachs
(2.82)
# 1,925
Out of 5,090 analysts
96
Total ratings
54%
Success rate
5.33%
Average return
Main Sectors:
Stocks Rated by Chris Shibutani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PCVX Vaxcyte | Maintains: Buy | $138 → $100 | $46.48 | +115.15% | 2 | Apr 1, 2025 | |
| ERAS Erasca | Maintains: Buy | $3.5 → $3 | $3.27 | -8.26% | 7 | Mar 21, 2025 | |
| MCRB Seres Therapeutics | Maintains: Sell | $20 → $15 | $16.66 | -9.96% | 4 | Mar 14, 2025 | |
| ALKS Alkermes | Maintains: Buy | $30 → $32 | $29.52 | +8.40% | 7 | Feb 14, 2025 | |
| BNTX BioNTech SE | Upgrades: Buy | $90 → $137 | $96.25 | +42.34% | 7 | Nov 8, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $30 → $33 | $20.32 | +62.40% | 3 | Nov 7, 2024 | |
| UTHR United Therapeutics | Maintains: Neutral | $243 → $302 | $489.31 | -38.28% | 4 | Nov 1, 2024 | |
| RPRX Royalty Pharma | Maintains: Buy | $50 → $51 | $39.73 | +28.37% | 3 | Aug 14, 2024 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $160 → $155 | $201.93 | -23.24% | 3 | Jul 19, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Neutral | $3 → $4 | $14.20 | -71.83% | 8 | Jul 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $20 | $7.14 | +180.11% | 5 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $650 → $723 | $1,010.31 | -28.44% | 6 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $29 → $26 | $17.64 | +47.39% | 1 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $134 → $153 | $155.51 | -1.61% | 2 | Jan 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $173 | $226.08 | -23.48% | 4 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $56.90 | - | 4 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $81 → $69 | $52.15 | +32.31% | 5 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $13 | $20.74 | -37.32% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $23 | $79.64 | -71.12% | 3 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $8.72 | +473.39% | 1 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $52 | $66.62 | -21.95% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $47 → $60 | $26.03 | +130.50% | 2 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $18 | $10.34 | +74.08% | 4 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $9.63 | +76.53% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.22 | - | 1 | Jul 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $5.98 | - | 1 | Feb 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $5.30 | - | 4 | Jan 24, 2018 |
Vaxcyte
Apr 1, 2025
Maintains: Buy
Price Target: $138 → $100
Current: $46.48
Upside: +115.15%
Erasca
Mar 21, 2025
Maintains: Buy
Price Target: $3.5 → $3
Current: $3.27
Upside: -8.26%
Seres Therapeutics
Mar 14, 2025
Maintains: Sell
Price Target: $20 → $15
Current: $16.66
Upside: -9.96%
Alkermes
Feb 14, 2025
Maintains: Buy
Price Target: $30 → $32
Current: $29.52
Upside: +8.40%
BioNTech SE
Nov 8, 2024
Upgrades: Buy
Price Target: $90 → $137
Current: $96.25
Upside: +42.34%
Syndax Pharmaceuticals
Nov 7, 2024
Maintains: Buy
Price Target: $30 → $33
Current: $20.32
Upside: +62.40%
United Therapeutics
Nov 1, 2024
Maintains: Neutral
Price Target: $243 → $302
Current: $489.31
Upside: -38.28%
Royalty Pharma
Aug 14, 2024
Maintains: Buy
Price Target: $50 → $51
Current: $39.73
Upside: +28.37%
Johnson & Johnson
Jul 19, 2024
Maintains: Neutral
Price Target: $160 → $155
Current: $201.93
Upside: -23.24%
Amylyx Pharmaceuticals
Jul 12, 2024
Maintains: Neutral
Price Target: $3 → $4
Current: $14.20
Upside: -71.83%
May 6, 2024
Maintains: Neutral
Price Target: $18 → $20
Current: $7.14
Upside: +180.11%
Apr 11, 2024
Maintains: Neutral
Price Target: $650 → $723
Current: $1,010.31
Upside: -28.44%
Mar 1, 2024
Maintains: Neutral
Price Target: $29 → $26
Current: $17.64
Upside: +47.39%
Jan 25, 2024
Maintains: Buy
Price Target: $134 → $153
Current: $155.51
Upside: -1.61%
Dec 11, 2023
Upgrades: Buy
Price Target: $173
Current: $226.08
Upside: -23.48%
Nov 9, 2023
Upgrades: Outperform
Price Target: n/a
Current: $56.90
Upside: -
Oct 30, 2023
Maintains: Buy
Price Target: $81 → $69
Current: $52.15
Upside: +32.31%
Mar 3, 2023
Maintains: Neutral
Price Target: $15 → $13
Current: $20.74
Upside: -37.32%
Mar 1, 2023
Maintains: Neutral
Price Target: $20 → $23
Current: $79.64
Upside: -71.12%
Dec 19, 2022
Initiates: Buy
Price Target: $50
Current: $8.72
Upside: +473.39%
Dec 16, 2022
Maintains: Buy
Price Target: $40 → $52
Current: $66.62
Upside: -21.95%
Dec 13, 2022
Upgrades: Buy
Price Target: $47 → $60
Current: $26.03
Upside: +130.50%
Nov 8, 2022
Maintains: Neutral
Price Target: $13 → $18
Current: $10.34
Upside: +74.08%
Sep 7, 2021
Initiates: Buy
Price Target: $17
Current: $9.63
Upside: +76.53%
Jul 14, 2020
Initiates: Outperform
Price Target: n/a
Current: $2.22
Upside: -
Feb 10, 2020
Initiates: Outperform
Price Target: n/a
Current: $5.98
Upside: -
Jan 24, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $5.30
Upside: -